(Q44646272)

5 December 2017

title

F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity (English)

1 reference

5 December 2017

0 references

7

J M Soucie

1 reference

5 December 2017

8

W Craig Hooper

1 reference

5 December 2017

C H Miller

1

1 reference

5 December 2017

J Benson

2

1 reference

5 December 2017

D Ellingsen

3

1 reference

5 December 2017

J Driggers

4

1 reference

5 December 2017

A Payne

5

1 reference

5 December 2017

F M Kelly

6

1 reference

5 December 2017

Hemophilia Inhibitor Research Study Investigators

9

1 reference

5 December 2017

publication date

21 November 2011

1 reference

5 December 2017

1 reference

5 December 2017

volume

18

1 reference

5 December 2017

issue

3

1 reference

5 December 2017

page(s)

375-382

1 reference

Genetic risk factors for inhibitors to factors VIII and IX.

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

Haemophilia A mutations in the UK: results of screening one-third of the population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

Risk factors for inhibitor formation in haemophilia: a prevalent case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

Inhibitors occur more frequently in African-American and Latino haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

Inhibitors of factor VIII in black patients with hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

Intensive peri-operative use of factor VIII and the Arg593-->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

Evidence that descendants of three founders constitute about 25% of hemophilia B in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

Modifier genes in haemophilia: their expansion in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

Detection of large duplications within the factor VIII gene by MLPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

Inhibitors in haemophilia: clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

Mild and moderate factor VIII deficiency: inhibitor risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02700.X

10.1111/J.1365-2516.2011.02700.X

21 January 2018

Identifiers

DOI

1 reference

release_mlbipxfcizfb3awz5bihzimyj4

5 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mlbipxfcizfb3awz5bihzimyj4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference